A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Sirukumab (Primary) ; Adalimumab
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SIRROUND-H
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 26 Feb 2018 Results published in the Annals of the Rheumatic Diseases.
    • 08 Nov 2017 Results of a sub-study (n=41) assessing ability of grey-scale US and PDS to evaluate changes in synovitis post treatment with Sirukumab and Adalimumab presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 08 Nov 2017 Results of a pooled safety analysis of five phase III trials (SIRROUND-D, -M, -H, -T and -LTE; n=2926) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top